FrancophonIA/ELRC3.0 huggingface dataset:
English: While keeping the syringe plunger pressed, turn the system upside down and draw the solution into the syringe by pulling the plunger back slowly.
Croatian: 11. Držeći klip štrcaljke stisnut, okrenite bočicu naopako i uvucite otopinu u štrcaljku polako povlačeći klip.
English: In May 2016, an open-label, randomised controlled trial aimed at addressing the incidence of inhibitors between the two classes (pdFVIII vs. rFVIII products) was published in the New England Journal of Medicine1.
Croatian: U svibnju 2016. u časopisu New England Journal of Medicine objavljeno je otvoreno randomizirano kontrolirano ispitivanje koje se bavilo incidencijom inhibitora u dvama razredima lijekova (s faktorom VIII dobivenim iz plazme u odnosu na lijekove s rekombinantnim faktorom VIII).
English: • one vial with solvent (6 mL clear glass type 1 vial with grey chlorobutyl rubber blend stopper and aluminium seal)
Croatian: • jednu bočicu koja sadrži otapalo (bočica od 6 ml od prozirnog stakla tipa 1 sa sivim čepom od klorobutilne gume i aluminijskim zatvaračem)
English: Table 5: Phase III incremental recovery results Study participants
Croatian: Tablica 5: Rezultati prirasta po jedinici doze u fazi III Ispitanici
English: For major surgery in particular, close monitoring of the replacement therapy by means of coagulation analysis must be carried out.
Croatian: Pozorno praćenje nadomjesnog liječenja u vidu analize koagulacije nužno je osobito u slučaju velikih kirurških zahvata.
English: Gently swirl the product vial with the transparent adapter attached until the substance is fully dissolved.
Croatian: Nježno vrtite bočicu s lijekom s pričvršćenim prozirnim dijelom nastavka sve dok se tvar potpuno ne otopi.
English: Early haemarthrosis, muscle bleeding or oral bleeding
Croatian: Početna hemartroza, krvarenje u mišiću ili usnoj šupljini
English: Do not use this medicine if you notice any particles or the solution is cloudy.
Croatian: Ovaj lijek se ne smije upotrijebiti ako primijetite vidljive čestice u otopini ili ako je otopinazamućena.
English: Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counter clockwise.
Croatian: Kada je otopina povučena u štrcaljku, čvrsto držite tijelo štrcaljke (držeći ju okrenutu klipom prema dolje) i odvojite prozirni dio Mix2Vial nastavka od štrcaljke okrećući ju u smjeru suprotnom od kazaljke na satu.
English: How to use Iblias
Croatian: Kako primjenjivati Iblias
English: You must filter the reconstituted product before administration to remove any possible particles in the solution.
Croatian: Pripremljeni lijek prije primjene morate filtrirati kako biste iz otopine uklonili moguće čestice.
English: Headache, dizziness common
Croatian: Glavobolja, omaglica često Disgeuzija manje često
English: The doctor should always adjust the dose and the frequency of administration according to your individual needs.
Croatian: Dozu i učestalost primjene ovog lijeka liječnik uvijek treba prilagoditi potrebama pojedinog bolesnika.
English: Tel: +385 (1) 631-1833
Croatian: PharmaSwiss d.o.o. Tel: +385 (1) 631-1833
English: Abdominal pain, abdominal discomfort, dyspepsia common
Croatian: Bol u abdomenu, nelagoda u abdomenu, dispepsija često
English: This trial, known as the SIPPET study (“Survey of Inhibitors in Plasma-Product Exposed Toddlers”) was conducted to evaluate the relative risk of inhibitors in patients treated with pdFVIII compared to rFVIII.
Croatian: Ovo ispitivanje, poznato kao SIPPET ispitivanje (Survey of Inhibitors in Plasma-Product Exposed Toddlers - ispitivanje inhibitora u male djece izložene lijekovima proizvedenima iz plazme),
English: How to store Iblias
Croatian: Kako čuvati Iblias
English: Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with IbliasIf such inhibitors occur, the condition will manifest itself as an insufficient clinical response.
Croatian: Do razvoja neutralizirajućih antitijela (inhibitora) može doći u bolesnika s hemofilijom A koji su liječeni faktorom VIII, uključujući Iblias.
English: Apply a tourniquet to your arm. 14.
Croatian: Postavite povesku na ruku.
English: • stomach pain or discomfort
Croatian: • bol ili nelagoda u trbuhu
English: • the severity of your haemophilia
Croatian: • težina hemofilije
English: You may be at risk of CVAD-related complications including local infections, bacteria in the blood (bacteraemia) and the formation of a blood clot in the blood vessel (thrombosis) where the catheter is inserted.
Croatian: • Vam je potrebno postaviti centralni venski kateter za primjenu lijeka Iblias možete imati povećan rizik od komplikacija povezanih s centralnim venskim kateterom, kao što su lokalne infekcije, bakterije u krvi (bakterijemija) i stvaranje krvnog ugruška u krvnoj žili (tromboza) u koju je uveden kateter.
English: Finally, apply a small pressure dressing to the injection site and consider if a plaster is necessary.
Croatian: Na kraju lagano stisnite mjesto injiciranja zavojem te razmotrite primjenu flastera.
English: Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration.
Croatian: Rekonstituirane lijekove za parenteralnu primjenu prije primjene treba vizualno pregledati na prisutnost čestica i promjenu boje.
English: METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous use.
Croatian: NAČIN I PUT(EVI) PRIMJENE LIJEKA Za primjenu u venu.
English: Detailed instructions for reconstitution and administration of Iblias using the Mix2Vial adapter:
Croatian: Detaljnje upute za pripremu za primjenu i primjenu lijeka Iblias uz pomoć Mix2Vial nastavka: Temeljito operite ruke sapunom i toplom vodom.
English: Open the Mix2Vial package by peeling away the lid. Do not remove the Mix2Vial from the blister package!
Croatian: Nemojte vaditi Mix2Vial nastavak iz blister pakiranja!
English: Iblias 250 IU powder and solvent for solution for injection Iblias 500 IU powder and solvent for solution for injection Iblias 1000 IU powder and solvent for solution for injection Iblias 2000 IU powder and solvent for solution for injection Iblias 3000 IU powder and solvent for solution for injection
Croatian: Iblias 250 IU prašak i otapalo za otopinu za injekciju Iblias 500 IU prašak i otapalo za otopinu za injekciju Iblias 1000 IU prašak i otapalo za otopinu za injekciju Iblias 2000 IU prašak i otapalo za otopinu za injekciju Iblias 3000 IU prašak i otapalo za otopinu za injekciju
English: The SIPPET study was an open-label, randomized, multi-centre, multi-national trial investigating the incidence of neutralising allo-antibodies in patients with severe congenital haemophilia A
Croatian: Ispitivanje SIPPET bilo je otvoreno, randomizirano, multicentrično, multinacionalno ispitivanje koje je istraživalo incidenciju neutralizirajućih alo-protutijela u bolesnika s teškom prirođenom hemofilijom A (koncentracija faktora VIII u plazmi < 1 %) pri primjeni koncentrata faktora VIII dobivenog iz plazme ili rekombinantnog faktora VIII.
English: • chest pain or discomfort
Croatian: • bol ili nelagoda u prsištu
English: Iblias 250 IU powder for solution for injection Iblias 500 IU powder for solution for injection Iblias 1000 IU powder for solution for injection Iblias 2000 IU powder for solution for injection Iblias 3000 IU powder for solution for injection recombinant human coagulation factor VIII (octocog alfa) Intravenous use.
Croatian: Iblias 250 IU prašak za otopinu za injekciju Iblias 500 IU prašak za otopinu za injekciju Iblias 1000 IU prašak za otopinu za injekciju Iblias 2000 IU prašak za otopinu za injekciju Iblias 3000 IU prašak za otopinu za injekciju rekombinantni ljudski koagulacijski faktor VIII (oktokog alfa)
English: 1 vial: 500 IU octocog alfa (200 IU/mL after reconstitution).
Croatian: 1 bočica: 500 IU oktokoga alfa (200 IU/ml nakon pripreme za primjenu).
English: Inject air into the product vial.
Croatian: Injicirajte zrak u bočicu s lijekom.
English: • rash/itchy rash
Croatian: • osip/osip praćen svrbežom
English: • your bleeding is not being controlled with your usual dose of Iblias.
Croatian: • se uobičajenom dozom lijeka Iblias ne zaustavlja krvarenje.
English: 1 vial: 3000 IU octocog alfa (600 IU/mL after reconstitution).
Croatian: 1 bočica: 3000 IU oktokoga alfa (600 IU/ml nakon pripreme za primjenu).
English: Speak to your doctor if you would like further information on this.
Croatian: Ako biste željeli dodatne informacije obratite se svom liječniku.
English: 1 vial: 2000 IU octocog alfa (400 IU/mL after reconstitution).
Croatian: 1 bočica: 2000 IU oktokoga alfa (400 IU/ml nakon pripreme za primjenu).
English: Hypersensitivity uncommon
Croatian: Preosjetljivost manje često
English: Discard the solvent vial with the blue Mix2Vial adapter attached.
Croatian: Bočicu s otapalom s pričvršćenim plavim dijelom Mix2Vial seta bacite.
English: Iblias 250 IU powder and solvent for solution for injection Iblias 500 IU powder and solvent for solution for injection Iblias 1000 IU powder and solvent for solution for injection Iblias 2000 IU powder and solvent for solution for injection Iblias 3000 IU powder and solvent for solution for injection Recombinant human coagulation factor VIII (octocog alfa)
Croatian: Iblias 250 IU prašak i otapalo za otopinu za injekciju Iblias 500 IU prašak i otapalo za otopinu za injekciju Iblias 1000 IU prašak i otapalo za otopinu za injekciju Iblias 2000 IU prašak i otapalo za otopinu za injekciju Iblias 3000 IU prašak i otapalo za otopinu za injekciju rekombinantni ljudski koagulacijski faktor VIII (oktokog alfa)
English: 250 IU (octocog alfa) (100 IU/mL after reconstitution).
Croatian: 250 IU (oktokoga alfa) (100 IU/ml nakon pripreme za primjenu).
English: How Iblias is given
Croatian: Kako se daje lijek Iblias
English: Q1 first quartile; Q3 third quartile
Croatian: ABR, engl. annualized bleed rate = stopa krvarenja na godišnjoj razini Q1 prva kvartila; Q3 treća kvartila
English: Invert the solvent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the product vial stopper.
Croatian: Okrenite bočicu s otapalom s pričvršćenim Mix2Vial setom i gurnite šiljak na prozirnom kraju nastavka ravno kroz čep bočice s lijekom.
English: 1 vial: 250 IU octocog alfa (100 IU/mL after reconstitution).
Croatian: 1 bočica: 250 IU oktokoga alfa (100 IU/ml nakon pripreme za primjenu).
English: • One mL Iblias 250 IU contains approximately 100 IU (250 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Iblias 250 IU nakon rekonstitucije s vodom za injekcije sadrži približno 100 IU (250 IU / 2,5 ml) rekombinantnog ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: • One mL Iblias 3000 IU contains approximately 600 IU (3000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Iblias 3000 IU nakon rekonstitucije s vodom za injekcije sadrži približno 600 IU (3000 IU / 5 ml) rekombinantnog ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: MARKETING AUTHORISATION HOLDER Bayer AG 51368 Leverkusen Germany
Croatian: Nositelj odobrenja za stavljanje lijeka u promet Bayer AG 51368 Leverkusen Njemačka
English: 1 vial: 1000 IU octocog alfa (400 IU/mL after reconstitution).
Croatian: 1 bočica: 1000 IU oktokoga alfa (400 IU/ml nakon pripreme za primjenu).
English: • One mL Iblias 500 IU contains approximately 200 IU (500 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Iblias 500 IU nakon rekonstitucije s vodom za injekcije sadrži približno 200 IU (500 IU / 2,5 ml) rekombinantnog ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: • One mL Iblias 1000 IU contains approximately 400 IU (1000 IU / 2.5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Iblias 1000 IU nakon rekonstitucije s vodom za injekcije sadrži približno 400 IU (1000 IU / 2,5 ml) rekombinantnog ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: • One mL Iblias 2000 IU contains approximately 400 IU (2000 IU / 5 mL) of recombinant human coagulation factor VIII (INN: octocog alfa) after reconstitution with water for injections.
Croatian: • Jedan ml lijeka Iblias 2000 IU nakon rekonstitucije s vodom za injekcije sadrži približno 400 IU (2000 IU / 5 ml) rekombinantnog ljudskog koagulacijskog faktora VIII (INN: oktokog alfa).
English: 500 IU (octocog alfa) (200 IU/mL after reconstitution).
Croatian: 500 IU (oktokoga alfa) (100 IU/ml nakon pripreme za primjenu).
English: 1000 IU (octocog alfa) (400 IU/mL after reconstitution).
Croatian: 1000 IU (oktokoga alfa) (100 IU/ml nakon pripreme za primjenu).
English: On Demand Treatment
Croatian: NAČIN PRIMJENE LIJEKA
English: 2000 IU (octocog alfa) (400 IU/mL after reconstitution).
Croatian: 2000 IU (oktokoga alfa) (100 IU/ml nakon pripreme za primjenu).
English: • flushing (redness of the face)
Croatian: • navale crvenila (crvenilo lica)
English: 3000 IU (octocog alfa) (600 IU/mL after reconstitution).
Croatian: 3000 IU (oktokoga alfa) (100 IU/ml nakon pripreme za primjenu).
English: SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Croatian: I DOHVATA DJECE Čuvati izvan pogleda i dohvata djece.
English: No cases of overdose with recombinant coagulation factor VIII have been reported.
Croatian: Ako primijenite više lijeka Iblias nego što ste trebali Nije zabilježen niti jedan slučaj predoziranja rekombinantnim koagulacijskim faktorom VIII.
English: 2 http://www.bloodjournal.org/content/109/11/4648.full.pdf 3 Gouw SC et al. PedNet and RODIN Study Group.
Croatian: U ispitivanju RODIN/Pednet također nisu utvrđeni dokazi o različitosti razreda u pogledu rizika od inhibitora između svih lijekova s faktorom VIII dobivenim iz plazme i s rekombinantnim faktorom http://www.bloodjournal.org/content/109/11/4648.full.pdf
English: Besides, as the evidence suggests that all human FVIII products carry a risk of inhibitor development, within the frequency of ‘very common' and ‘uncommon', for PUPs
Croatian: Osim toga, budući da dokazi ukazuju na to da kod svih lijekova s ljudskim faktorom VIII postoji rizik od razvoja inhibitora unutar raspona učestalosti „vrlo često” u prethodno neliječenih bolesnika i „manje često” u prethodno liječenih bolesnika, PRAC je preporučio da se informacije o lijeku za te lijekove usklade s tim učestalostima, osim ako to nije opravdano s obzirom na podatke specifične za lijek.
English: MA (EU) number (Invented) name Strength Pharmaceutical form Route of administration Immediate Packaging Pack size EU/1/08/499/002 Valdoxan
Croatian: Broj (EU) odobrenja (Zaštićeno) ime Doza Farmaceutski oblik Put primjene Unutarnje pakovanje Veličina pakovanja EU/1/08/499/002 Valdoxan
English: A typical dose will range from 7.5 mg (3.75 ml) to 25 mg (12.5 ml) once a week.
Croatian: Uobičajena doza kreće se od 7,5 mg (3,75 ml) do 25 mg (12,5 ml) jednom tjedno.
English: • If you have any questions about your treatment, speak to your doctor, nurse or pharmacist.
Croatian: • Imate li pitanja o svom liječenju, obratite se svom liječniku, medicinskoj sestri ili ljekarniku.
English: More information about Jylamvo can be found on the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003756/human_ med_002083.jsp
Croatian: Više informacija o lijeku Jylamvo nalazi se na internetskim stranicama Agencije: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003756 /human_med_002083.jsp
English: You should follow your healthcare professional's instructions.
Croatian: Morate se pridržavati uputa zdravstvenog radnika.
English: Dose in mg 5 mg
Croatian: Doza u mg 5 mg
English: Any mistakes in measuring the dose could lead to patients receiving too much or too little of the medicine potentially with serious consequences.
Croatian: Svaka pogreška u mjerenju doze može dovesti do toga da bolesnici prime preveliku ili premalu dozu lijeka, s potencijalno ozbiljnim posljedicama.
English: • If you have any signs or symptoms of overdose contact your doctor immediately.
Croatian: • Ako vam se pojave znakovi ili simptomi predoziranja, odmah se obratite liječniku.
English: • Your doctor, nurse or pharmacist will explain you how to withdraw the required dose using the syringe provided.
Croatian: • Liječnik, medicinska sestra ili ljekarnik objasnit će Vam kako izvući potrebnu dozu lijeka pomoću štrcaljke priložene uz lijek.
English: Only after such an assessment should patients start to self-administer Jylamvo at home.
Croatian: Tek nakon takve procjene bolesnici mogu početi sami primjenjivati Jylamvo kod kuće.
English: • Jylamvo (methotrexate 2mg/ml)
Croatian: • Jylamvo (metotreksat 2mg/ml)
English: Jylamvo is a medicine that is used for the treatment of the following inflammatory conditions:
Croatian: Jylamvo je lijek koji se primjenjuje za liječenje sljedećih upalnih stanja:
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom29 March 2017 EMA/81869/2017
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: Guidance on the amount to withdraw for the different doses in mg is given in the table below:
Croatian: Upute o količini koju treba izvući za različite doze, navedene su u mg u tablici ispod:
English: Amount in ml to be withdrawn
Croatian: Količina koju treba izvući u ml
English: It is also important that patients are carefully instructed on how to withdraw a dose from the bottle using the syringe provided.
Croatian: Također je važno bolesnike pažljivo uputiti kako će iz bočice izvući dozu lijeka pomoću priložene štrcaljke.
English: If the medicine is used for psoriasis or arthritis and is inadvertently taken once a day instead of once a week, this could lead to serious harm.
Croatian: Ako se lijek primjenjuje za liječenje psorijaze ili artritisa i zabunom se uzima jednom dnevno umjesto jednom tjedno, to može dovesti do ozbiljnih oštećenja.
English: Healthcare professionals expected to prescribe and dispense Jylamvo will be given an educational guide to ensure that the medicine is used correctly.
Croatian: Zdravstveni radnici za koje se očekuje da će propisivati i izdavati Jylamvo dobit će edukacijski materijal kako bi se osigurala pravilna primjena lijeka.
English: When prescribing Jylamvo, doctors should always prescribe the dose in mg and ml.
Croatian: Kada se propisuje Jylamvo, liječnici uvijek moraju propisati dozu u mg i ml.
English: The syringe is graduated in ml while the dose is expressed in mg.
Croatian: Štrcaljka je graduirana u ml, a doza je izražena u mg.
English: • An oral syringe is provided with Jylamvo and it is important that only this syringe is used to withdraw the dose.
Croatian: • Uz Jylamvo je priložena oralna štrcaljka i važno je da se za izvlačenje doze koristi samo ta štrcaljka.
English: Jylamvo is also used to treat adults and children over the age of 3 years who have acute lymphoblastic leukaemia (ALL), a cancer of white blood cells called lymphoblasts.
Croatian: Jylamvo se koristi za liječenje odraslih i djece starije od 3 godine s akutnom limfoblastičnom leukemijom (ALL), rakom bijelih krvnih stanica koji se nazivaju limfoblastima.
English: • Healthcare professionals should assess each patient to determine whether they are able to measure the dose correctly.
Croatian: • Zdravstveni radnici moraju za svakog bolesnika procijeniti je li sposoban pravilno izmjeriti dozu.
English: For acute lymphoblastic leukaemia (ALL), the dose is usually higher and given more frequently.
Croatian: Za liječenje akutne limfoblastične leukemije (ALL) doza je obično viša i primjenjuje se češće.
English: • For acute lymphoblastic leukaemia (ALL), the dose is usually higher and you may need to take Jylamvo more frequently.
Croatian: • Kod akutne limfoblastične leukemije (ALL) doze su obično više i možda ćete Jylamvo trebati uzimati češće.
English: • Patients should be monitored for signs and symptoms of overdose, such as bleeding, unusual feeling of weakness, ulcers in the mouth, feeling sick, vomiting, black or bloody stools, coughing up blood or vomiting blood and reduced urine output.
Croatian: • Bolesnike treba pratiti zbog znakova i simptoma predoziranja, kao što su krvarenje, neuobičajen osjećaj slabosti, ranice u ustima, mučnina, povraćanje, crna ili krvava stolica, iskašljavanje ili povraćanje krvi te smanjeno mokrenje.
English: • severe juvenile idiopathic arthritis (JIA), a joint disease in children;
Croatian: • teški oblik juvenilnog idiopatskog artritisa (JIA), bolest zglobova u djece;
English: Jylamvo, an oral solution containing methotrexate, is used to treat arthritis and the skin disease psoriasis, as well as a type of blood cancer called acute lymphoblastic leukaemia (ALL).
Croatian: Jylamvo, oralna otopina koja sadrži metotreksat, primjenjuje se za liječenje artritisa i kožne bolesti psorijaze, kao i vrste raka krvi pod nazivom akutna limfoblastična leukemija (ALL).
English: • With every prescription patients should be reminded on how to measure the dose correctly.
Croatian: • Kod svakog propisivanja lijeka bolesnike treba podsjetiti kako pravilno izmjeriti dozu.
English: The educational guide will advise healthcare professionals that for arthritis and psoriasis Jylamvo must be taken once a week.
Croatian: Edukacijski materijal upozorit će zdravstvene radnike da se za liječenje artritisa i psorijaze Jylamvo mora uzimati jednom tjedno.
English: • severe disabling psoriasis, a disease causing red, scaly patches on the skin.
Croatian: • teška onesposobljujuća psorijaza, bolest koja uzrokuje crvene ljuskave površine na koži;
English: Healthcare professionals should carefully explain to patients when and how to take their dose
Croatian: Zdravstveni radnici moraju bolesnicima pažljivo objasniti kada i kako će uzimati dozu
English: It is important that healthcare professionals carefully explain to patients when and how they should take their dose.
Croatian: Važno je da zdravstveni radnici pažljivo objasne bolesnicima kada i kako moraju uzimati dozu.
English: These include: bleeding, unusual feeling of weakness, ulcers in the mouth, feeling sick, vomiting, black or bloody stools, coughing up blood or vomiting blood and a reduced urine production.
Croatian: Oni uključuju: krvarenje, neuobičajen osjećaj slabosti, ranice u ustima, mučninu, povraćanje, crnu ili krvavu stolicu, iskašljavanje ili povraćanje krvi te smanjeno mokrenje.
English: • For arthritis and skin diseases, Jylamvo must be taken once a week only, on the same day each week.
Croatian: • U slučaju artritisa i kožnih bolesti, Jylamvo se smije primjenjivati samo jednom tjedno, istog dana u tjednu.
English: Methotrexate is never taken every day for arthritis or skin diseases.
Croatian: Za liječenje artritisa ili kožnih bolesti metotreksat se nikada ne primjenjuje svakoga dana.
English: • Patients should be counselled on taking the correct dose correctly: for arthritis and psoriasis, Jylamvo must be taken once a week only, on the same day each week.
Croatian: • Bolesnicima treba savjetovati kako pravilno uzimati točnu dozu; za liječenje artritisa i psorijaze Jylamvo se smije uzimati samo jednom tjedno, određenog dana u tjednu.
English: • active rheumatoid arthritis, an inflammatory joint disease;
Croatian: • aktivni reumatoidni artritis, upalna bolest zglobova;
English: • Jylamvo is available as an oral solution that contains 2 mg/ml of methotrexate.
Croatian: • Jylamvo je dostupan kao oralna otopina koja sadrži 2 mg/ml metotreksata.
English: • Jylamvo is available as an oral solution that contains 2 mg of methotrexate per ml.
Croatian: • Jylamvo je dostupan kao oralna otopina koja sadrži 2 mg metotreksata po ml.
English: • severe psoriatic arthritis, an inflammatory joint disease that occurs in patients with psoriasis.
Croatian: • teški psorijatični artritis, upala zglobova koja se pojavljuje u bolesnika s psorijazom.